The Potential Benefit of Expedited Development and Approval Programs in Precision Medicine.
drugs
expedited review
orphan drugs
precision medicine
regulation
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
14 Jan 2021
14 Jan 2021
Historique:
received:
21
12
2020
revised:
07
01
2021
accepted:
11
01
2021
entrez:
20
1
2021
pubmed:
21
1
2021
medline:
21
1
2021
Statut:
epublish
Résumé
Increased understanding of the molecular causes of disease has begun to fulfill the promise of precision medicine with the development of targeted drugs, particularly for serious diseases with unmet needs. The drug approval regulatory process is a critical component to the continued growth of precision medicine drugs and devices. To facilitate the development and approval process of drugs for serious unmet needs, four expedited approval programs have been developed in the US: priority review, accelerated approval, fast track, and breakthrough therapy programs. To determine if expedited approval programs are fulfilling the intended goals, we reviewed drug approvals by the US Food and Drug Administration (FDA) between 2011 and 2017 for new molecular entities (NMEs). From 2011 through 2017, the FDA approved 250 NMEs, ranging from 27 approvals in 2013 to 46 in 2017. The NME approvals spanned 22 different disease classes; almost one-third of all NMEs were for oncology treatments. As these pathways are utilized more, additional legislative changes may be needed to re-align incentives to promote continued development of innovative drugs for serious unmet needs in a safe, efficacious, and affordable manner.
Sections du résumé
BACKGROUND
BACKGROUND
Increased understanding of the molecular causes of disease has begun to fulfill the promise of precision medicine with the development of targeted drugs, particularly for serious diseases with unmet needs. The drug approval regulatory process is a critical component to the continued growth of precision medicine drugs and devices. To facilitate the development and approval process of drugs for serious unmet needs, four expedited approval programs have been developed in the US: priority review, accelerated approval, fast track, and breakthrough therapy programs.
METHODS
METHODS
To determine if expedited approval programs are fulfilling the intended goals, we reviewed drug approvals by the US Food and Drug Administration (FDA) between 2011 and 2017 for new molecular entities (NMEs).
RESULTS
RESULTS
From 2011 through 2017, the FDA approved 250 NMEs, ranging from 27 approvals in 2013 to 46 in 2017. The NME approvals spanned 22 different disease classes; almost one-third of all NMEs were for oncology treatments.
CONCLUSIONS
CONCLUSIONS
As these pathways are utilized more, additional legislative changes may be needed to re-align incentives to promote continued development of innovative drugs for serious unmet needs in a safe, efficacious, and affordable manner.
Identifiants
pubmed: 33466644
pii: jpm11010045
doi: 10.3390/jpm11010045
pmc: PMC7828670
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Drug Saf. 2017 Jun;40(6):497-503
pubmed: 28342075
J Clin Oncol. 2018 Jun 20;36(18):1805-1812
pubmed: 29688832
Health Aff (Millwood). 2017 Aug 1;36(8):1408-1415
pubmed: 28784733
Am J Med. 2020 Jun;133(6):675-678
pubmed: 32145207
JAMA. 2018 Jul 17;320(3):301-303
pubmed: 30027239
JAMA. 2020 Jan 14;323(2):164-176
pubmed: 31935033
N Engl J Med. 2017 Dec 7;377(23):2278-2286
pubmed: 29211663
N Engl J Med. 2011 Mar 24;364(12):1144-53
pubmed: 21428770
Am J Med. 2018 Sep;131(9):1025-1033
pubmed: 29626430
J Pharmacol Pharmacother. 2016 Apr-Jun;7(2):57-61
pubmed: 27440949
Arch Intern Med. 1998 Jan 26;158(2):166-72
pubmed: 9448555
Health Aff (Millwood). 2014 Aug;33(8):1453-9
pubmed: 25092848
N Engl J Med. 2014 Mar 27;370(13):1252-8
pubmed: 24670173
JAMA. 2002 Jul 24-31;288(4):475-82
pubmed: 12132978
BMJ. 2017 Sep 7;358:j3837
pubmed: 28882831
JAMA. 2017 Dec 5;318(21):2137-2138
pubmed: 29209711
Ther Deliv. 2010 Nov;1(5):615-9
pubmed: 22833952
BMJ. 2015 Sep 23;351:h4633
pubmed: 26400751
JAMA. 2017 May 9;317(18):1854-1863
pubmed: 28492899
J Family Med Prim Care. 2020 Jan 28;9(1):105-114
pubmed: 32110574
J Health Econ. 2016 May;47:20-33
pubmed: 26928437
Pharmacotherapy. 2018 Sep;38(9):967-980
pubmed: 30043413
Lancet. 2020 Mar 21;395(10228):998-1010
pubmed: 32199487
Perspect Clin Res. 2017 Oct-Dec;8(4):176-179
pubmed: 29109935
Health Aff (Millwood). 2016 Mar;35(3):464-70
pubmed: 26953301
J Clin Oncol. 2009 Sep 10;27(26):4398-405
pubmed: 19636013
Am J Med. 2019 Sep;132(9):1038-1043
pubmed: 30853471
Clin Cancer Res. 2021 Jan 1;27(1):11-14
pubmed: 32816899
J Clin Oncol. 2018 Jun 20;36(18):1798-1804
pubmed: 29641296
PLoS One. 2016 Oct 21;11(10):e0164681
pubmed: 27768685
Res Social Adm Pharm. 2020 Jun;16(6):844-847
pubmed: 31812502
JAMA. 2017 Aug 15;318(7):626-636
pubmed: 28810023
Nat Rev Clin Oncol. 2020 Mar;17(3):140-146
pubmed: 32020042
N Engl J Med. 2017 May 25;376(21):2001-2004
pubmed: 28538133
Ther Innov Regul Sci. 2017 Jan;51(1):24-28
pubmed: 30235999
Chest. 2018 Jun;153(6):1309-1314
pubmed: 29325986
Lancet. 2020 Mar 21;395(10228):986-997
pubmed: 32199486